Share this article
Share this article
DUBLIN, April 22, 2021 /PRNewswire/ Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engineering platform optimised to manufacture off-the-shelf cell-based therapies for cancer treatment.
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under Project Ireland 2040 and run by the Department of Enterprise Trade and Employment with support from Enterprise Ireland.
Automated and Closed Cell Therapy Processing Systems Markets, 2030 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Date Time
Biotech company founded by University of Toronto researchers secures US$85 million in financing Juan Carlos Zúñiga-Pflücker (left), of the Temerty Faculty of Medicine and Sunnybrook Health Sciences Centre, and Peter Zandstra, who is now at UBC, founded Notch Therapeutics at U of T in 2018.
Notch was founded in 2018 by two pioneers of cell therapy research, Juan Carlos Zúñiga-Pflücker, chair of the department of immunology at the University of Toronto’s Temerty Faculty of Medicine and a senior scientist at Sunnybrook Health Sciences Centre, and Peter Zandstra, who was then at U of T and is now a professor at the University of British Columbia, but continues to collaborate with U of T’s Institute for Biomedical Engineering. The company was supported by MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine.
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
Published: Feb 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company s proprietary Engineered Thymic Niche (ETN) platform. The financing will